| Patent Number |
Title Of Patent |
Date Issued |
| 7592318 |
88kDa tumorigenic growth factor and antagonists |
September 22, 2009 |
| This invention relates to products and methods for treating cancer and for diagnosing tumorigenicity and other diseases associated with alteration in GP88 expression or action. Antagonists to an 88 KDa autocrine growth and tumorigenicity stimulator are provided which inhibit its expressi |
| 7560095 |
Cancer specific monoclonal antibodies |
July 14, 2009 |
| Novel monoclonal antibodies and binding fragments thereof specific to human breast cancer, lung cancer, colon cancer and other cancers. The monoclonal antibody does not bind to the cell surface of normal human tissues. The corresponding cancer-specific antigen or antigens with an app |
| 7411045 |
Autocrine growth factor receptor antibodies and methods |
August 12, 2008 |
| Disclosed herein are antitumor compositions and methods of interfering with the biological activity of PC cell derived growth factor (PCDGF), anti-PCDGF receptor antibodies, fragments thereof, and methods of making anti-PCDGF receptor antibodies. The methods involve inhibiting the pr |
| 7368428 |
Compositions and methods for restoring sensitivity of tumor cells to antitumor therapy and induc |
May 6, 2008 |
| Methods and compositions for restoring sensitivity to the antitumorigenic effects of antiestrogen therapy and/or cytotoxic therapy and inducing cell apoptosis are provided. Contacting tumor cells to GP88 antagonists (e.g., anti-GP88 antibodies, anti-GP88 antisense nucleic acids, GP88 |
| 7183384 |
Monoclonal antibody 7H11 reactive with human cancer |
February 27, 2007 |
| Novel monoclonal antibodies and binding fragments thereof specific to human breast cancer, lung cancer, colon cancer and other cancers. The monoclonal antibody does not bind to the cell surface of normal human tissues. The corresponding cancer-specific antigen with an apparent molecu |
| 7091047 |
Methods and kits for diagnosing tumorigenicity |
August 15, 2006 |
| Methods and kits for diagnosing tumorigenicity by measuring the concentration of GP88 in blood, plasma, serum, saliva, urine and other biological fluids. The methods and kits detect GP88 in biological fluids at a concentration as low as about 0.1 to 10 nanograms per milliliter and ar |
| 6881548 |
Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic |
April 19, 2005 |
| Methods and kits for diagnosing tumorigenicity and for determining whether a cancer patient is resistant to the pharmacological effects of antiestrogen therapy. Increased levels of the PCDGF (GP88) growth factor are indicative of tumorigenicity and resistance to the pharmacological e |
| 6824775 |
88kDa tumorigenic growth factor and antagonists |
November 30, 2004 |
| This invention relates to products and methods for treating cancer and for diagnosing tumorigenicity and other diseases associated with alteration in GP88 expressing or action. Antagonists to an 88 KDa autocrine growth and tumorigenicity stimulator are provided which inhibit its expressi |
| 6720159 |
88KDA tumorigenic growth factor and antagonists |
April 13, 2004 |
| This invention relates to products and methods for treating cancer and for diagnosing tumorigenicity and other diseases associated with alteration in GP88 expression or action. Antagonists to an 88 KDa autocrine growth and tumorigenicity stimulator are provided which inhibit its expressi |
| 6670183 |
88kDa tumorigenic growth factor and antagonists |
December 30, 2003 |
| This invention relates to products and methods for treating cancer and for diagnosing tumorigenicity and other diseases associated with alteration in GP88 expression or action. Antagonists to an 88 KDa autocrine growth and tumorigenicity stimulator are provided which inhibit its expressi |
